Pfizer plugs back in

While Pfizer Inc. (NYSE:PFE) retreated from neuroscience R&D in January, the pharma hasn’t cut the cord yet. Ramped up allocations to neuroscience out of its latest $600 million venture investment give Pfizer the ability to assess the right time to re-enter the space.

Through Pfizer Ventures, the pharma plans to allocate about $150 million of the new funds to early stage neuroscience companies...